08.07.20Clinical Trials Begin for Combination of Interferon Beta-1A and Remdesivir
08.06.20Ofatumumab Reduced Annualized Relapse Rate in MS in Phase 3 Clinical Trials
08.05.20DHODH Inhibitor Reduces Lesions Significantly in Relapsing-Remitting MS
Neurologists need to have a palliative care skill set.
Jessica M. Baker, MD
Symptoms of Lewy Body Dementia Induced by Herpes Zoster Encephalitis
Ryan Verity, MD; Andrew Kirk, MD, FRCPC; and Gary Hunter, MD, FRCPC, CSCN(EEG)
Myasthenia Gravis Treatment
There are both disease-modifying and symptom-reducing treatments available and emerging treatment possibilities.
Vanessa Baute Penry, MD, and Rachana Gandhi Mehta, MD
07.14.20Expanded Disability Status Scale Available on Digital Platform
06.25.20New Resource Center for People Living with Multiple Sclerosis
06.22.20Enrollment Begins for Phase 1b Clinical Trial of T-cell Immunotherapy for Progressive Multiple Sclerosis
06.12.20FDA Approves Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder
06.09.20Phase 3 Trial of MSC-NTF Stem Cells for ALS Receives Continued Funding
Multiple Sclerosis Minute: The Central Vein Sign in Diagnosis of Multiple Sclerosis
More accurate diagnosis is needed for multiple sclerosis and the central vein sign may be the needed imaging biomarker.
Marwa Kaisey, MD, and Nancy L. Sicotte MD, FAAN
Teleneurology Billing and Coding
Perspectives on coding evaluation & management during the COVID-19 pandemic.
Brad Klein, MD, MBA, FAAN, FAHS, FAANEM, and Raissa Villanueva MD, MPH, FAAN
Something can almost always be offered virtually for people with neuro-ophthalmologic conditions.
Melissa W. Ko, MD; Kevin E. Lai, MD; and Devin D. Mackay, MD
06.04.20Investigation of Foralumab for Alzheimer Disease Treatment Will Continue to Phase 2
06.01.20Ozanimod, a New Oral Treatment for Relapsing Multiple Sclerosis, Now Available
05.28.20FDA Removes Category C Warning of Possible Risk in Pregnancy and Breast Feeding for MS Treatment Interferon Beta-1a
05.24.20T-Cell Immunotherapy for Progressive MS Shows Safety and Efficacy
05.23.20Continued Safety and Tolerability of Satralizumab for NMOSD
05.23.20Evobrutinib Treatment Reduced Annualized Relapse Rate Sustained in Open-Label Extension Study